Chronic Kidney Disease

Webster, Angela C; Nagler, Evi; Morton, Rachael L.; Masson, Philip

doi:10.1016/s0140-6736(16)32064-5

Cited by 2,736 publications

(2,395 citation statements)

References 86 publications

Supporting

Mentioning

2,025

Contrasting

Unclassified

126

Order By: Relevance

“…CKD in connection with CVD-, CHF-, and COPDrelated parameters (13/23) People with CKD are 5-10 times more likely to die prematurely than they are to progress to ESRD. This increased risk of death rises exponentially as kidney function worsens and is largely attributable to death from CVD [37]. CVD and CKD are intricately connected, as CVD continues to be the most common cause of morbidity and mortality in patients with CKD and ESRD [8].…”

Section: General Aspects For Wearable Medical Devicesmentioning

confidence: 99%

Wearable sensors: can they benefit patients with chronic kidney disease?

Wieringa

Broers

Kooman

et al. 2017

Expert Review of Medical Devices

View full text Add to dashboard Cite

Introduction: This article ponders upon wearable medical measurement devices in relation to Chronic Kidney Disease (CKD) and its' associated comorbidities -and whether these might benefit CKD-patients. We aimed to map the intersection(s) of nephrology and wearable sensor technology to help technologists understand medical aspects, and clinicians to understand technological possibilities that are available (or soon will become so). Areas covered: A structured literature search on main comorbidities and complications CKD patients suffer from, was used to steer mini-reviews on wearable sensor technologies clustered around 3 themes being: Cardiovascular-related, diabetes-related and physical fitness/frailty. This review excludes wearable dialysis -although also strongly enabled by miniaturization -because that highly important theme deserves separate in-depth reviewing. Expert commentary: Continuous progress in integrated electronics miniaturization enormously lowered price, size, weight and energy consumption of electronic sensors, processing power, memory and wireless connectivity. These combined factors boost opportunities for wearable medical sensors. Such devices can be regarded as enablers for: Remote monitoring, influencing human behaviour (exercise, dietary), enhanced home care, remote consults, patient education and peer networks. However, to make wearable medical devices succeed, the challenge to fit them into health care structures will be dominant over the challenge to realize the bare technologies themselves. ARTICLE HISTORY

show abstract

Section: General Aspects For Wearable Medical Devicesmentioning

confidence: 99%

Wearable sensors: can they benefit patients with chronic kidney disease?

Wieringa

Broers

Kooman

et al. 2017

Expert Review of Medical Devices

View full text Add to dashboard Cite

show abstract

“…Chronic kidney disease (CKD) is a significant contributor to this burden in both developed and developing nations, with approximately 80% of people with CKD living in low to middle income countries (Mills et al, 2015). The disease is classified into stages according to the estimated glomerular filtration rate (eGFR) with stage five also termed end-stage kidney disease (ESKD) when kidney replacement therapy (KRT) is required to sustain life (Webster, Nagler, Morton, & Masson, 2017). Recognised as one of the worldwide public health problems, CKD is burdensome on individuals and families because of its effects on daily life and the extensive and long-term healthcare required.…”

mentioning

confidence: 99%

“…Chronic kidney disease (CKD) is defined globally as either kidney damage with urine, imaging, and histologic abnormalities, or a low estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73m² for 3 months or longer (Johnson et al, 2013;Webster et al, 2017). The impairment of kidney function in CKD is irreversible (Johnson et al, 2013;Webster et al, 2017), and the reduction in kidney function is classified into five stages based on eGFR (see Table 1.1).…”

mentioning

confidence: 99%

“…The impairment of kidney function in CKD is irreversible (Johnson et al, 2013;Webster et al, 2017), and the reduction in kidney function is classified into five stages based on eGFR (see Table 1.1). The first stage is when eGFR is normal or increased to equal or greater than 90 mL/min/1.73m².…”

mentioning

confidence: 99%

“…In stage 4, eGFR is severely reduced (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) mL/min/1.73m²), and stage 5 is when eGFR is less than 15 mL/min/1.73m². This stage is also called end-stage kidney disease (ESKD) (Johnson et al, 2013;Webster et al, 2017). (Johnson et al, 2013;Webster et al, 2017) Abbreviation: eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; D, dialysis, T, transplantation Prevalence…”

mentioning

confidence: 99%

See 2 more Smart Citations

Self-Management Program for People with Chronic Kidney Disease in Vietnam: A Pragmatic Randomised Controlled Trial

Nguyen¹

View full text Add to dashboard Cite

show abstract

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes

et al. 2021

View full text Add to dashboard Cite

IMPORTANCE Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose excretion and reduce cardiovascular (CV) deaths and hospitalizations for heart failure (HHF) among patients with type 2 diabetes. The relative CV efficacy and safety of dapagliflozin according to baseline kidney function and albuminuria status are unknown. OBJECTIVE To assess the CV efficacy and safety of dapagliflozin according to baseline estimated glomerular filtration rate (eGFR) and urinary albumin to creatinine ratio (UACR). DESIGN, SETTING, AND PARTICIPANTSThis secondary analysis of the randomized clinical trial Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 compared dapagliflozin vs placebo in 17 160 patients with type 2 diabetes and a baseline creatinine clearance of 60 mL/min or higher. Patients were categorized according to prespecified subgroups of baseline eGFR (<60 vs Ն60 mL/min/1.73 m 2 ), urinary albumin to creatinine ratio (UACR; <30 vs Ն30 mg/g), and of chronic kidney disease (CKD) markers using these subgroups (0, 1, or 2). The study was conducted from May 2013 to September 2018. INTERVENTIONS Dapagliflozin vs placebo. MAIN OUTCOMES AND MEASURESThe dual primary end points were major adverse cardiovascular events (myocardial infarction, stroke, and CV death) and the composite of CV death or HHF.RESULTS At baseline, 1265 patients (7.4%) had an eGFR below 60 mL/min/1.73 m 2 , and 5199 patients (30.9%) had albuminuria. Among patients having data for both eGFR and UACR, 10 958 patients (65.1%) had an eGFR equal to or higher than 60 mL/min/1.73 m 2 and an UACR below 30 mg/g (mean [SD] age, 63.7 [6.7] years; 40.1% women), 5336 patients (31.7%) had either an eGFR below 60 mL/min/1.73 m 2 or albuminuria (mean [SD] age, 64.1 [7.1] years; 32.6% women), and 548 patients (3.3%) had both (mean [SD] age, 66.8 [6.9] years; 30.5% women). In the placebo group, patients with more CKD markers had higher event rates at 4 years as assessed using the Kaplan-Meier approach for the composite of CV death or HHF (3.9% for 0 markers, 8.3% for 1 marker, and 17.4% for 2 markers) and major adverse cardiovascular events (7.5% for 0 markers, 11.6% for 1 marker, and 18.9% for 2 markers). Estimates for relative risk reductions for the composite of CV death or HHF and for major adverse cardiovascular events were generally consistent across subgroups (both P > .24 for interaction), although greater absolute risk reductions were observed with more markers of CKD. The absolute risk difference for the composite of CV death or HHF was greater for patients with more markers of CKD (0 markers, −0.5%; 1 marker, −1.0%; and 2 markers, −8.3%; P = .02 for interaction). The numbers of amputations, cases of diabetic ketoacidosis, fractures, and major hypoglycemic events were balanced or numerically lower with dapagliflozin compared with placebo for patients with an eGFR below 60 mL/min/1.73 m 2 and an UACR of 30 mg/g or higher.CONCLUSIONS AND RELEVANCE The effect of dapagliflozin on the relative risk for CV...

show abstract

Chronic Kidney Disease

Cited by 2,736 publications

References 86 publications

Wearable sensors: can they benefit patients with chronic kidney disease?

Wearable sensors: can they benefit patients with chronic kidney disease?

Self-Management Program for People with Chronic Kidney Disease in Vietnam: A Pragmatic Randomised Controlled Trial

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes

Contact Info

Product

Resources

About